Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
360Dx7h
Accelerate Diagnostics Submits Wave Platform, Gram-Negative Test to FDA
The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while its full-year 2024 revenues declined 3 percent.
360Dx7h
Accelerate Diagnostics Submits Wave Platform and Gram-Negative Test to FDA
The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while full-year 2024 revenues declined 3 percent.
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance
Accelerate Diagnostics, Inc. (Nasdaq: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture ...
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
Fierce Pharma13h
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Medicare coverage for Lyme disease
Typically, healthcare professionals prescribe antibiotics, such as amoxicillin, doxycycline, and cefuroxime axetil, to treat the early stages of Lyme disease.
Medindia23h
Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 ...
Novartis gets third FDA approval for oral Fabhalta
Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the ...
Le Lézard1d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, ...
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update
Fourth Quarter 2024 and Recent Developments: The Phase 2 Tailwind study represents the second successful clinical trial for AP-PA02, Armata's lead pulmonary candidate, which was first evaluated in ...
US FDA expands approval for Alnylam's drug to treat rare heart disease
U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...